PDS Biotechnology Corp annual report, FY2015

Filing identity and reporting period

Important mismatch: The request identifies PDS Biotechnology Corp., but the supplied Form 10-K is for Edge Therapeutics, Inc. (ticker EDGE). This summary reflects the supplied filing, not PDS Biotechnology. It covers the fiscal year ended December 31, 2015; fourth-quarter figures are unaudited.

Business context

Edge was a clinical-stage biotechnology company with no approved products or product revenue. Its lead candidate, EG-1962, is a sustained-release nimodipine formulation for aneurysmal subarachnoid hemorrhage (aSAH). EG-1964, for recurrent chronic subdural hematoma bleeding, remained in development. The company completed its IPO in October 2015.

Financial results and liquidity

For Q4 2015, total operating expenses were $8.9 million, net loss was $8.0 million, and net loss attributable to common stockholders was $8.1 million; quarterly loss per share was $0.30. No revenue-based margins are applicable.

Cash increased substantially following financing: the IPO generated approximately $82.8 million in net proceeds and an April preferred-stock financing generated approximately $52.4 million. At year-end, current assets were $131.3 million and current liabilities $8.6 million. Debt included $2.3 million current and $3.0 million long-term; the loan carries a base rate of 9.95% and matures March 1, 2018. Management said available cash was expected to fund operations through the anticipated 2018 full readout of the planned EG-1962 Phase 3 trial, subject to significant execution and cost uncertainties.

Material changes and unusual items

• Net loss rose 130% year over year as operating expenses approximately doubled. R&D growth reflected EG-1962 trial activity, EG-1964 development, and increased personnel; G&A also increased with staffing, stock compensation, professional fees, and public-company costs.
• 2015 other expense included a $1.9 million warrant remeasurement loss; the liability-classified warrants were reclassified to equity at the IPO. Preferred-stock dividends of $4.4 million increased the loss attributable to common stockholders beyond net loss.
• All preferred shares converted to common stock at the IPO. Year-end common shares outstanding were 28.8 million; 4.3 million stock options and 0.6 million warrants were also outstanding.

Outlook, commentary, and principal risks

• The NEWTON Phase 1/2 trial met its safety, tolerability, maximum-tolerated-dose, and pharmacokinetic objectives. In exploratory 90-day results, favorable outcomes were reported for 60% of EG-1962 recipients (27/45) versus 28% of oral-nimodipine controls (5/18). These small early-stage results are not proof of Phase 3 efficacy; the 1,200 mg cohort was not tolerable, and 600 mg was selected as the planned Phase 3 dose.
• Management planned a randomized, double-blind Phase 3 study of about 375 patients at approximately 65 centers, with an interim analysis around 210 patients and enrollment/evaluation anticipated to take up to 24 months. Trial initiation was expected in mid-2016. EG-1962 had U.S. and European orphan designation; the company expected to pursue the U.S. 505(b)(2) pathway.
• Key uncertainties include whether one pivotal trial will suffice, successful enrollment and manufacturing, clinical benefit and safety in a larger trial, and demonstrating clinical superiority to Nymalize to address its U.S. orphan-drug exclusivity through May 2020.
• Oakwood was the sole manufacturer of EG-1962 for the planned Phase 3 study; the company also relied on single-source suppliers for key materials. Supply interruption could delay development.
• Other risks include continued operating losses and possible future financing or dilution, debt covenants and repayment obligations, third-party and regulatory dependencies, intellectual-property exposure, and uncertain coverage, reimbursement, pricing, and commercial adoption. EG-1964 was preclinical, with an IND submission targeted for 2017.

Most important facts for investors to verify

• Confirm issuer identity: the supplied filing is Edge Therapeutics, not PDS Biotechnology.
• Review the full audited financial statements, cash-flow detail, debt terms, and assumptions supporting management’s cash runway estimate.
• Check subsequent updates on Phase 3 start, trial design, enrollment, interim analysis, results, and regulatory requirements.
• Assess the strength and limitations of the exploratory NEWTON data and the implications of Nymalize’s orphan exclusivity.
• Verify manufacturing readiness and supplier alternatives, as well as potential dilution from options, warrants, and future financing.